11th Milan Congress on Innovative Anticancer Therapy - 11th Edition

The 11th "Milan Congress on Innovative Anticancer Therapy" will present leading international experts in the field of immuno-oncology and cancer cell signaling to investigate the potentials, opportunities and challenges of immunotherapy and targeted therapies. The newest therapeutic approaches will be discussed in the context of the COVID-19 epidemic. Increased knowledge of the molecular mechanisms responsible for neoplastic transformation, the biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, has allowed us to identify and apply more effective biological and immunological anticancer treatments. To date, immuno-biotherapy is a continuously evolving treatment modality and is currently integrated into the treatment algorithms of several different tumor types. Combination treatments based on immune checkpoint inhibitors (ICI) with either targeted therapy, radiotherapy or standard chemotherapy have recently been introduced in clinical practice. Rationale, pro and contra, and the identification of a specific subset of patients who could benefit from these approaches will be discussed. This conference explores topics that will appeal to clinicians, as well as to, basic, translational, and clinical scientists ranging from academia to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, and provide the audience with a broad overview of the most recent achievements in biological and immunological cancer therapy. Lastly, a wide spectrum of evolving topics in cancer research such as epigenetic drugs and CART cells will be analyzed in view of their introduction in the clinical setting.